e-therapeutics plc
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and automated evaluation; and GalOmic, a proprietary siRNA chemistry that generates potent and long-acting RNAi medicines. Its preclinical products are ETX-312 to trea… Read more
e-therapeutics plc (ETXPF) - Total Liabilities
Latest total liabilities as of July 2024: $2.02 Million USD
Based on the latest financial reports, e-therapeutics plc (ETXPF) has total liabilities worth $2.02 Million USD as of July 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
e-therapeutics plc - Total Liabilities Trend (2007–2024)
This chart illustrates how e-therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
e-therapeutics plc Competitors by Total Liabilities
The table below lists competitors of e-therapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Petron Malaysia Refining Marketing
KLSE:3042
|
Malaysia | RM1.52 Billion |
|
River Valley Community Bancorp
PINK:RVCB
|
USA | $552.79 Million |
|
DeviceENG.CO.Ltd
KQ:187870
|
Korea | ₩81.14 Billion |
|
PADAUK Technology Co. Ltd
TWO:6716
|
Taiwan | NT$401.85 Million |
|
Mgame Corp
KQ:058630
|
Korea | ₩18.30 Billion |
|
FELIX Gold Ltd
AU:FXG
|
Australia | AU$2.60 Million |
|
Guardian Metal Resources PLC
OTCQX:GMTLF
|
USA | $2.90 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down e-therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how e-therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for e-therapeutics plc (2007–2024)
The table below shows the annual total liabilities of e-therapeutics plc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-01-31 | $2.98 Million | +86.47% |
| 2023-01-31 | $1.60 Million | -33.66% |
| 2022-01-31 | $2.41 Million | +310.27% |
| 2021-01-31 | $586.36K | +56.63% |
| 2020-01-31 | $374.37K | -59.75% |
| 2019-01-31 | $930.02K | -36.13% |
| 2018-01-31 | $1.46 Million | -40.67% |
| 2017-01-31 | $2.45 Million | +49.69% |
| 2016-01-31 | $1.64 Million | +44.73% |
| 2015-01-31 | $1.13 Million | +12.96% |
| 2014-01-31 | $1.00 Million | +12.95% |
| 2013-01-31 | $888.00K | +63.24% |
| 2012-01-31 | $544.00K | -60.75% |
| 2011-01-31 | $1.39 Million | +12.50% |
| 2010-01-31 | $1.23 Million | +317.63% |
| 2009-01-31 | $295.00K | +28.82% |
| 2008-01-31 | $229.00K | +133.67% |
| 2007-01-31 | $98.00K | -- |